Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from May 28, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 26, 2026 — +6.9% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$1,060.00 – $1,110.00Entry zone — fair-value band

$1,112.23Published — price the day we called it

$1,234.57Target — the price the thesis aimed for

$1,292.65Peak — highest point inside the window, not a realized return

$1,189.41Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 32 days.

At window close

+6.9%

realized, from the publication price to the last close inside the window

Peak gain

+16.2%

peak, from the publication price — not a realized return

S&P 500, same window

+1.8%

SPY over the identical days, dividend-adjusted

Window close

$1,189.41

last close inside the window, ended August 26, 2026

Peak price

$1,292.65

peak on August 19, 2026 — not a realized return

Days to target

The thesis — published May 28, 2026

Predicted growth

+11%

over the measurement window

Target price

$1,234.57

the price the thesis aimed for

Entry zone

$1,060.00 – $1,110.00

the fair-value band we waited for

Price at publication

$1,112.23

published May 28, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly is a top healthcare growth company because its weight-loss medicines are in high demand, the drug pipeline and recent buys expand its business, and execution and profits are strong. After a powerful run, the short-term view is cautious: the position looks best as quality exposure on pullbacks rather than expecting fresh rapid gains.

Primary drivers

Market leader in obesity drugs driving big sales growth
New drugs and deals widen the company's product lineup
Positive media and analyst attention supports momentum
Strong profits help justify growth after recent gains

How it played out

LLY: target reached in 32 days

Lyra published a short-term thesis for 11% growth from a price of $1,112.23. The thesis pointed to demand for weight-loss medicines, a broader pipeline and recent deals, positive attention, and strong profits. It also warned that rapid fresh gains were less certain after the earlier run.

The shares reached the $1,234.57 target in 32 days. They later peaked at $1,292.65 on August 19, a 16.2% gain. By August 26, they had fallen back to $1,189.41, but the target had already been reached inside the window. The thesis played out.

What happened during the window

On June 7, Lilly reported new weight-loss study results for Foundayo. On August 5, the company reported that second-quarter revenue rose 48% to $23.0 billion and raised its full-year guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals